Cardiac Arrest Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Cardiac Arrest Treatment Market is segmented By Treatment Type (Drugs (BetaBlockers, Vasopressors, Anti-Arrhythmic Drugs, Anticholinergic Drugs, Corticosteroids, Fibrinolytic Drugs, and Others), By Medical Devices (Defibrillators, Cardiac Resynchronization Therapy, and Others) ), By Distribution Channel (Hospitals, Independent Pharmacies, and others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Cardiac Arrest Treatment Market Size

Global Cardiac Arrest Treatment Market size was valued at US$ 16,230 million in 2021 and is estimated to reach US$ 24,690 million by 2031, growing at a CAGR of 9.21% during the forecast period 2024-2031.

Cardiac arrest is a sudden and abrupt loss of heart function, consciousness, and apnea. It originates from an electrical disturbance caused in the heart due to a lag in electrical signal impulses. The primary cause of cardiac arrest is abnormal heart rhythm like ventricular tachycardia.

Market Summary

For More Insights Request Free Sample

Market Dynamics

The cardiac arrest treatment market growth is driven by the rise in cardiovascular diseases, rising sedentary lifestyle, increase in the geriatric population, and research activities.

The rising sedentary lifestyle is expected to drive the market growth     

The rising sedentary lifestyle is expected to boost the market over the forecast period. As per World Health Organization, sedentary lifestyles kill many people around the world. Insufficient physical activity is the 4th leading risk factor for mortality. Approximately 3.2 million deaths and 32.1 million DALYs (representing about 2.1% of global DALYs) each year are attributable to insufficient physical activity. People who are insufficiently physically active have a 20% to 30% increased risk of all-cause mortality compared to those who engage in at least 30 minutes of mode physical activity most days of the week. Prevalence of insufficiently physically active persons aged 18+ years (defined as less than 150 minutes of moderate-intensity activity per week, or equivalent).

The presence of research and development activities for the treatment of cardiac arrest is expected to boost the market. For instance, in Aug 29, 2022, Bayer showed that Kerendia cut the incidence of sudden cardiac death across a broad range of patients with early- to late-stage CKD and diabetes. The result came from a prespecified, pooled analysis of certain patients in the Fidelio-DKD and Figaro-DKD studies. While Kerendia narrowly missed the statistical significance bar for cutting all-cause and cardiovascular mortality in the overall study populations, a prespecified analysis of patients with CKD and type 2 diabetes was more favourable for the drug.

The high cost of cardiac arrest treatment will hamper the growth of the market  

However, the lack of availability of healthcare professionals in developing countries and the stringent regulations for the approval of cardiac devices are restraining the market. Commercial challenges due to the availability of safe and generic treatment options have become a major reason to abandon cardiovascular development

COVID-19 Impact Analysis on Market

The appearance of COVID-19 considerably impacted the global cardiac arrest treatment market. According to the research article published in Best Practice and Research: Clinical Anesthesiology, 2020, a combined risk was associated with cardiac surgery during the COVID-19 pandemic in which both patients and well healthcare workers were at higher risk of infection.

Additionally, as per the study results published in the journal of Annals of Thoracic Surgery, 2020, an estimated 53% decrease in the total cardiac surgery volume was observed in the United States in 2020 as compared to 2019, which was majorly attributed to the impact of COVID-19 pandemic.

Moreover, there are serious concerns about the long-term worsening of cardiovascular health outcomes due to a lack of timely diagnosis. There are very few multiple stakeholders for patient access to cardiovascular treatment and therapeutics.

Also, the devices like stethoscopes may increase the risk of the virus when used to listen to and identify specific heart sounds such as clicks, murmurs and rubs of the Covid-19 positive patient.

Additionally, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that Treatment types remain available and protect their supply chain.

In addition, hospitals have also transferred their personnel availability from cardiac departments to other departments in need, such as EDs or intensive care units (ICU). All these factors are expected to affect the market growth. Nevertheless, this slowdown in growth is anticipated to be temporary, and in the long run, the market is expected to have significant growth.

Market Segmentation Analysis

The reconstructive joint replacements segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)          

The beta-blocker segment is expected to boost the market over the period of the forecast. This is owing to the increased use of beta-blockers for cardiac arrest treatment. Beta-blockers became a prescription drug for recovering heart attack patients. However, many patients who are at higher risk for developing cardiovascular disease cannot tolerate these blood pressure-reducing medications, including those with chronic obstructive pulmonary disease (COPD) and asthma, the elderly, and diabetics.  

Beta-blockers are a class of medicines commonly used to treat many problems involving your heart and circulatory system. They also are sometimes used to treat conditions related to the brain and nervous system. Because beta receptors are found in several places throughout the body, so beta-blockers can treat many issues and conditions. Beta-blockers cause the heart to beat slowly and with less force, lowering blood pressure. Beta-blockers also help widen veins and arteries to improve blood flow.

Market Geographical Share

North America region holds the largest market share of the global cardiac arrest treatment market

North America dominates the market for cardiac arrest treatment and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the high adoption rate of CRT for cardiac arrest treatment among cardiologists and heart specialists and the presence of a large number of AED centers. The increase in the incidence of cardiovascular disorders and the advancements in medical devices for the treatment of cardiac arrest is expected to boost the market.

The Heart and Stroke Statistics - 2022 Update report was released by the American Heart Association. According to the report, cardiac arrest remains a public health crisis. Nearly 90% of all out-of-hospital cardiac arrests (OHCA) that occur in the United States each year are deadly. An estimated 356,461 people, or almost 1,000 people each day, are estimated to experience non-traumatic OHCA as determined by EMS. Survival to hospital discharge after EMS-treated cardiac arrest languishes at about 10%. Thus, these factors are driving the growth of the market in the forecast period.

Companies and Competitive Landscape

The cardiac arrest treatment market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market are Koninklijke Philips N.V., ZOLL Medical Corporation, GE Healthcare, Stryker, Boston Scientific Corporation, Cardiac Science Corporation (Aurora Capital Group), Bristol-Myers Squibb Company, and Abbott. among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the cardiac arrest treatment market globally.

Novartis International AG

Overview:

Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland, and Cambridge, Massachusetts, United States. It is one of the largest pharmaceutical companies in the world.     

Treatment type Portfolio:

ENTRESTO: This Treatment type is used to treat certain types of heart failure. It may help you live longer and lower your chance of having to go to the hospital for heart failure. This Treatment type contains 2 medications: sacubitril and valsartan.

The global cardiac arrest treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.